Galectin Therapeutics Inc.
Clinical trials sponsored by Galectin Therapeutics Inc., explained in plain language.
Galectin Therapeutics Inc.
GALT
NASDAQ
A biopharmaceutical company developing galectin inhibitors for fibrosis and cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.